Krishna Institute of Medical Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
KIMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts less than Nifty Smallcap 250 and 5.7 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
KIMS has reported audited standalone and consolidated financial results for FY 2025-26. Consolidated total income stood at Rs 16,120 million, an increase from approximately Rs 13,000 million in the prior year, representing ~24% revenue growth. Profit after tax (attributable to owners) grew to Rs 2,220 million from ~Rs 1,100 million in the prior year, a near doubling of PAT. The auditors, S.R. Batliboi & Associates LLP, have issued an UNMODIFIED (clean) opinion. An exceptional item of Rs 74 million was recorded due to one-time increase in employee benefit provisions following implementation of the new Labour Codes effective November 21, 2025. Three subsidiaries reported combined net loss of Rs 215 million for the year. The Board also approved appointment of new Cost Auditors, Senior Management Personnel (CFO, Company Secretary, CRO), and re-designated Mr. Adwik Bollineni as Executive Director (he is son of CMD and brother of Director & CEO, indicating a related party transaction).
Strong financial performance with near doubling of PAT and 24% revenue growth. Clean audit opinion is positive. Related party re-designation of a family member of promoters should be monitored for governance implications.